Emis, listed on the AIM junior market in London, provides IT software and services to GP clinics across the UK
City & Finance Reporter for the Daily Mail
WHO IS IT?
Emis, listed on the London AIM junior market, provides IT software and services to GP clinics across the UK. At present, it has a 56% market share.
Emis enables doctors in different parts of the NHS to quickly access a patient's records, help pharmacies manage inventory, and provide patient information services.
WHAT IS THE LAST?
It was buying companies in an attempt to expand, and last month it acquired Dovetail Digital, a £ 2.5 million health technology company.
Emis has not been without problems in the past – this week announced it has reached a £ 11.2 million deal with the NHS for failures in its NHS Digital deal this year. The one related to reporting obligations, and Emis is confident that the problems have been solved.
WHO DOES IT SAVE?
Fund manager Liontrust is the largest shareholder, while the start-up holder Octopus Investments and the Invesco investment company are both in the top ten. There are also some lesser-known names, including Primestone Capital and Evenlode.
WHY YOU MUST INVEST
George Salmon, an analyst at Hargreaves Lansdown, says: "Offering a better NHS is something we all want and infrastructure improvement is an economical way to do it." Emis interprets this trend well. "
Health care is not so exposed to fatal jumps in the economy, he adds, and software providers generally have strong cash flows so they can provide a steady stream of dividends.
AND WHY YOU DO NOT HAVE
Salmon points out that Emis did not necessarily progress as fast as he could have hoped, and the fine supported by the NHS could make investors wary.
He adds: "The acquisition of Ascribe in 2013 of 57.5 million pounds did not produce the expected results, contributing to a rocky run in recent years".
And of course, the NHS pressures make it a difficult customer.